Clinical Evaluation of Transarterial Infusion Chemotherapy for Advanced Esophageal Cancer

• Published in: Journal of Cancer Vol. 12; no. 5; pp. 1493 - 1498
• Main Authors: Yin, Mei-Pan, Xie, Peng-Fei, Zhao, Yue, He, Wei, Ma, Yao-Zhen, Li, Chun-Xia, Li, Zhen, Zeng, Yan-Wei, Wu, Gang
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 2021; Ivyspring International Publisher
• Subjects: Blood; Blood vessels; Cancer therapies; Cardiovascular disease; Catheters; Chemotherapy; Diabetes; Drugs; Dysphagia; Esophageal cancer; Fistula; Hemoglobin; Hypertension; Medical imaging; Medical prognosis; Ostomy; Patients; Radiation therapy; Remission (Medicine); Research Paper; Surgery; Thyroid gland; Veins & arteries; Complication; Transarterial infusion chemotherapy; Interventional radiology; Esophageal cancer
• ISSN: 1837-9664; 1837-9664
• DOI: 10.7150/JCA.46877

: Most esophageal cancer patients are diagnosed at an advanced stage when there are few effective treatments. Transarterial infusion chemotherapy is a local chemotherapy method wherein chemotherapeutic drugs are directly injected into tumor vessels. : Transarterial infusion chemotherapy was performed on advanced esophageal cancer patients once a month, and each patient underwent 1-3 treatments. The clinical results, complications, and effectiveness rates of each treatment episode were recorded and analyzed. : Transarterial infusion chemotherapy was successfully performed in all patients, and no severe complications such as paraplegia or death were noted. Complete response, partial response, and stable disease were noted in 17.3% (13/75), 77.3% (58/75), and 5.3% (4/75) of cases after transarterial infusion chemotherapy, respectively. The total treatment efficacy (complete response + partial response) was 94.7%. All cases exhibited improvement in clinical stage, with a marked decrease in dysphagia. Subsequent treatments were administered to 13 patients, including radical radiation in 7 and chemotherapy in 6. During follow-up, death was caused by progressive carcinoma in 20, tumor-related pneumatic infection and respiratory failure in 11, and gastrointestinal hemorrhage in 17. The median survival time was 15 months and the 1-year survival rate was 58.1%. : Transarterial infusion chemotherapy may be safely and effectively used for treatment of advanced esophageal cancer.